Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 5/2015

01-05-2015 | Original Paper

Wls promotes the proliferation of breast cancer cells via Wnt signaling

Authors: Dong Lu, Ying Li, Qing-Ru Liu, Qi Wu, Hao Zhang, Peng Xie, Qingling Wang

Published in: Medical Oncology | Issue 5/2015

Login to get access

Abstract

The Wnt secretion protein Wntless (Wls)/GPR177 has been reported to be involved in the development of several human cancers. However, the biological significance of Wls in breast cancer progression has not been clarified. In this study, we show for the first time that Wls is an important molecule related to breast cancer. We find that Wls expression is markedly increased in clinical breast tumors compared with adjacent noncancerous tissues. Downregulation of Wls by short-hairpin RNA severely suppressed the proliferation of breast cancer cells. Wls is a core Wnt signaling component, and we show that knockdown of Wls is sufficient to inhibit Wnt secretion and its downstream signaling. Taken together, these results indicate that Wls contributes to the proliferation of breast cancer cells by regulating Wnt signaling. Therefore, Wls could be a novel therapeutic target for inhibiting cell growth in breast cancer.
Literature
1.
Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007;99:1152–61.CrossRefPubMed
2.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMed
3.
Zeng Z, Lin H, Zhao X, et al. Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Clin Cancer Res. 2012;18:4059–69.CrossRefPubMed
4.
Banziger C, Soldini D, Schutt C, Zipperlen P, Hausmann G, Basler K. Wntless, a conserved membrane protein dedicated to the secretion of Wnt proteins from signaling cells. Cell. 2006;125:509–22.CrossRefPubMed
5.
Yu J, Chia J, Canning CA, Jones CM, Bard FA, Virshup DM. WLS retrograde transport to the endoplasmic reticulum during Wnt secretion. Dev Cell. 2014;29:277–91.CrossRefPubMed
6.
7.
Bartscherer K, Pelte N, Ingelfinger D, Boutros M. Secretion of Wnt ligands requires Evi, a conserved transmembrane protein. Cell. 2006;125:523–33.CrossRefPubMed
8.
Hausmann G, Banziger C, Basler K. Helping wingless take flight: how WNT proteins are secreted. Nat Rev Mol Cell Biol. 2007;8:331–6.CrossRefPubMed
9.
Fu J, Jiang M, Mirando AJ, Yu HM, Hsu W. Reciprocal regulation of Wnt and Gpr177/mouse Wntless is required for embryonic axis formation. Proc Natl Acad Sci USA. 2009;106:18598–603.CrossRefPubMedCentralPubMed
10.
Maruyama EO, Yu HM, Jiang M, Fu J, Hsu W. Gpr177 deficiency impairs mammary development and prohibits Wnt-induced tumorigenesis. PLoS One. 2013;8:e56644.CrossRefPubMedCentralPubMed
11.
12.
Voloshanenko O, Erdmann G, Dubash TD, et al. Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. Nat Commun. 2013;4:2610.CrossRefPubMedCentralPubMed
13.
Stewart J, James J, McCluggage GW, et al. Analysis of Wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression. Mod Pathol. 2015;28:428–36.
14.
Chiou SS, Wang LT, Huang SB, et al. Wntless (GPR177) expression correlates with poor prognosis in B-cell precursor acute lymphoblastic leukemia via Wnt signaling. Carcinogenesis. 2014;35:2357–64.CrossRefPubMed
15.
Yang PT, Anastas JN, Toroni RA, et al. WLS inhibits melanoma cell proliferation through the ss-catenin signalling pathway and induces spontaneous metastasis. EMBO Mol Med. 2012;4:1294–307.CrossRefPubMedCentralPubMed
16.
17.
Kaur N, Chettiar S, Rathod S, et al. Wnt3a mediated activation of Wnt/beta-catenin signaling promotes tumor progression in glioblastoma. Mol Cell Neurosci. 2013;54:44–57.CrossRefPubMed
18.
Clevers H, Loh KM, Nusse R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science. 2014;346:1248012.CrossRefPubMed
19.
20.
21.
Bartek J. DNA damage response, genetic instability and cancer: from mechanistic insights to personalized treatment. Mol Oncol. 2011;5:303–7.CrossRefPubMed
22.
Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8:387–98.CrossRefPubMed
23.
Lindvall C, Bu W, Williams BO, Li Y. Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell Rev. 2007;3:157–68.CrossRefPubMed
24.
25.
Behrens J, Lustig B. The Wnt connection to tumorigenesis. Int J Develop Biol. 2004;48:477–87.CrossRef
26.
Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discovery. 2006;5:997–1014.CrossRef
27.
Banziger C, Soldini D, Schutt C, Zipperlen P, Hausmann G, Basler K. Wntless, a conserved membrane protein dedicated to the secretion of Wnt proteins from signaling cells. Cell. 2006;125:509–22.CrossRefPubMed
Metadata
Title
Wls promotes the proliferation of breast cancer cells via Wnt signaling
Authors
Dong Lu
Ying Li
Qing-Ru Liu
Qi Wu
Hao Zhang
Peng Xie
Qingling Wang
Publication date
01-05-2015
Publisher
Springer US
Published in
Medical Oncology / Issue 5/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-015-0585-z

Other articles of this Issue 5/2015

Medical Oncology 5/2015 Go to the issue

Original Paper

Tight junction protein claudin-6 inhibits growth and induces the apoptosis of cervical carcinoma cells in vitro and in vivo

Original Paper

1H-MRS evaluation of breast lesions by using total choline signal-to-noise ratio as an indicator of malignancy: a meta-analysis

Original Paper

Endothelial cell protein C receptor promotes MGC803 gastric cancer cells proliferation and migration by activating ERK1/2

Original Paper

Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases

Original Paper

Chemoradiation therapy reduces aldehyde dehydrogenase 1 expression in cervical cancer but does not improve patient survival

Original Paper

The role of CD29-ILK-Akt signaling-mediated epithelial–mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits